ArticleTrials2025
Real-time 3D confirmation of complete ablation with margins as a local cure for colorectal liver metastases: the ACCLAIM trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05265169 (Ablation With Confirmation of Colorectal Liver Metastases), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective Trial for Microwave Ablation as a Local Cure
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Thermal ablation versus liver resection for small colorectal liver metastases (≤ 3 cm): a systematic review and meta-analysis of randomized and propensity score-matched studies.Surgical endoscopy · 2026Pooled it
- [Interventional therapeutic strategies for metastatic liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Thermal Ablation for Colorectal Liver Metastases: Current Evidence and Future Horizons.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- The effects of measurement errors on minimum ablative margins after thermal ablation of liver tumors: a simulation study.CVIR oncology · 2026Article
- Artificial Intelligence in Thermal Ablation: Current Applications and Future Directions in Microwave Technologies.Biomimetics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTreatment failure and local tumor progression (LTP) after thermal ablation (TA) have been attributed to insufficient minimal margin (MM) ablation zone coverage of the target tumor.
methodsThis prospective, open-label, multicenter, international trial will enroll approximately 275 patients with one to three colorectal liver metastases (CLM) (for a total of 330 tumors) each up to 2.5 cm in largest diameter, eligible for local cure using microwave ablation (MWA). Any FDA cleared or CE-marked MWA device can be used. MWA will be performed with the intent to create a MM of at least 5 mm and ideally ≥ 10 mm. MM size will be documented intraprocedurally with contrast-enhanced computed tomography (CECT) immediately post-MWA and again within 4-8 weeks after MWA using any FDA cleared or CE-marked image-processing software to provide a 3D assessment of the ablation zone (AZ) and MM. An independent assessment of the MM by a central physician reviewer with expertise on AZ assessments will be conducted within 7 days of the MWA with 3D image-processing confirmation software and again within 7 days after the 4-8 weeks post-MWA CECT. A MM of 5.0 mm will represent the necessary condition for technical success of MWA. For MMs under 5 mm, repeat MWA will be performed within the same session whenever feasible/safe, and/or within 30 days from detection of the insufficient MM to create a sufficient MM (> 5 mm). MM size will be correlated with time to local tumor progression (TTLP). Local progression-free (LPFS) and hepatic disease-free survival (accounting for all tumors ablated) stratified by MM of 5.0-9.9 mm and ≥ 10.0 mm will be assessed with Kaplan-Meier and competing risk methodologies. DISCUSSION: This study aims to demonstrate that MWA of CLM ≤ 2.5 cm with 3D image-processing confirmation software of MM over 5 mm achieves definitive local tumor control. This will help establish margin confirmation as a new standard of care for MWA of CLM.
trial registrationClinicalTrials.gov NCT05265169. Registered on January 13, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.